cabozantinib,atezolizumab
exelixis,roche
['bladder', 'cabozantinib']
maintenance cabozantinib after 1st line chemo not showing activity in 1st line bladder cancer #asco22. further evidence that vegf targeted therapy does not have significant activity in bladder cancer. the last single agent vegf randomised trial? 
Interested in Urology Cancers, biomarkers and drug development.